

# Writing Your RDD Poster Abstract

## Please follow these instructions and deadlines carefully.

This allows Respiratory Drug Delivery to distribute high quality abstracts showcasing your work to conference participants.

Your poster abstract must be 3 to 5 pages long, when printed double spaced with one-inch margins using Arial 12-point font. Please reduce the amount of text to accommodate inserted tables or figures. All text in figures, graphs and diagrams must be legible with acronyms spelled out whenever possible.

### Deadlines

Poster Abstract submitted online: ..... **January 23, 2026**  
Reviewer returns comments to primary author by e-mail: ..... **February 6–March 6, 2026**  
Final Abstract e-mailed to Publisher: ..... **ASAP but no later than March 30, 2026**  
Copyright transfer emailed to Respiratory Drug Delivery: ..... **March 30, 2026**

### Abstract Title, Author(s), Institution(s) and Key Words

On the first page of your abstract, please include the following sections in Arial 12-point font:

- The title of your abstract should appear first in “Title Case” (this means only the first letter of major words and appropriate abbreviations are capitalized). Please do not state conclusions in the title.

Benchmarking of Particle Engineering Strategies for Nasal Powder Delivery: Characterization of Nasal Deposition using the Alberta Idealized Nasal Inlet

- The primary author should be listed, followed by any other authors. Only capitalize the first letter of each name only. Include full first and last names, and the middle initial of all authors. Initials should be followed by a period. Do not include administrative titles, degrees, telephone numbers and e-mail addresses of authors. RDD will obtain this information from the web submission form and communicate with only the primary author – it is their responsibility to contact co-authors when necessary.

Patricia Henriques,<sup>1,2</sup> Cláudia Costa<sup>1</sup>, António Serôdio<sup>1</sup>, Ana Fortuna<sup>2,3</sup> and Slavomíra Doktorovová<sup>1</sup>

<sup>1</sup>Hovione FarmaCiência SA, Lumiar, Portugal

<sup>2</sup>Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal

<sup>3</sup>CIBIT/ICNAS, Coimbra Institute for Biomedical Imaging and Translational Research, University of Coimbra, Coimbra, Portugal

The address of the primary author, including their company name (and optionally their department), city and country, should be listed. If the authors are associated with different institutions, the author(s) and institution should be correctly associated with superscripted Arabic numbers (1, 2, 3, etc.).

- After the author information, please list **no more than 6 keywords or phrases**. Please avoid commonly used words such as "Aerosol", "Inhaled" and "Pulmonary Drug Delivery", since these are not helpful for search purposes. Keywords should be listed in lower case, unless using a proper name. If using an acronym, please spell it out, followed by the acronym in parentheses. Please enter the same keywords in the abstract submission web form.

**Keywords:** nasal powder, spray dried microparticles, chimera agglomerates, aerodynamic performance, Alberta Idealized Nasal Inlet

**Body of the Text:** Please write under the following section headings in the order shown

- **INTRODUCTION:** Please keep this section short. Its purpose is to explain why your work is important and provide any background information a reader will need to understand the work you plan to present.
- **MAIN SECTIONS:** Please use appropriate subheadings of your choice, to divide your work into appropriate sections, for example, METHODS, DATA ANALYSIS, RESULTS. Keep the subheadings short. Always include a CONCLUSIONS section that does not repeat your results but does explain how you interpret the significance of your results.
- Use of footnotes is permitted but should be limited as much as possible.
- **ACKNOWLEDGEMENTS AND DISCLOSURES:** These should be in a separate section immediately following the conclusions. Sources of financial support or affiliations with an organization that could be perceived as a real or apparent conflict of interest must be disclosed.
- **REFERENCES:** All references, including URLs, must be numbered consecutively, in square brackets, in the order in which they are cited in the text. References are not included in the 5-page limit. Examples of the *Respiratory Drug Delivery* reference style are shown below. Authors using EndNote, Reference Manager, etc. can select *Respiratory Research*, which is similar to our style.

**Journal Articles:**

Chen JZ, Finlay WH, Martin A: *In vitro* regional deposition of nasal sprays in an idealized nasal inlet: Comparison with in vivo gamma scintigraphy. *Pharm. Res.* 2022, 39: 3021–3028.

**Books:**

Newman SP: *Respiratory Drug Delivery: Essential Theory and Practice*. RDD Online / Virginia Commonwealth University, Richmond: 2009.

**Book Chapters:**

Dalby RN, Byron PR: *In vitro* testing of inhaled products. In *Respiratory Drug Delivery: Essential Theory and Practice*. Edited by Newman SP. RDD Online / Virginia Commonwealth University, Richmond: 2009: 59-96.

**Websites:**

AstraZeneca: Symbicort Prescribing Information [<https://www.mysymbicort.com>]. Accessed June 1, 2024.

**Patents:**

Pearl J, Byron PR, Lichtman AH, Martin BR: Delta-9 Tetrahydrocannabinol (Delta-9 THC) solution metered dose inhalers (pMDIs) and methods of use. U.S. Patent 6,713,048, March 30, 2004.

**Regulatory Guidance Documents:**

FDA Draft Guidance (2018): Guidance for Industry (Draft). Metered dose inhaler (MDI) and dry powder inhaler (DPI) drug products: Quality Considerations.

**Conference Abstracts:**

Lewis DA, Green JL, Turner R, Johnson RD, Lewis DI: HFA152a MDI design: Matching the *in-vitro* performance of HFA227 and HFA134a MDIs. In *Respiratory Drug Delivery 2023*. Edited by Dalby RN, Pearl J, Suman JD, Young PM, Traini D, Watts A. RDD Online; Richmond, VA: 2023: 295–298.

Moura C, Vicente J, Palha M, Neves F, Aguiar-Ricardo A, Costa E: Screening and optimization of formulation and process parameters for the manufacture of inhalable composite particles by spray drying. In *Drug Delivery to the Lungs 2014*. The Aerosol Society. Bristol, UK: 2014: Poster 63 [or page numbers].

## Tables, Figures and Other Artwork

We encourage the use of tables & figures to present data. These can be embedded in your text or appear on separate pages at the end with their insertion point indicated, for example, by stating, <FIGURE 1 INSERTED HERE>. All tables and figures must be consecutively numbered and include a caption.

All text in tables, graphs, diagrams and photographs must be legible. Arial 12-point font is preferred. Thicken lines to ensure they are clearly visible. Use acronyms and legends identical to those included in your text.

**Tables:** Black and white is preferred for tables. Do not include .jpg images of tables unless you are using a published table with permission of the copyright holder. Instead, make tables using Microsoft Word's Table feature or another application that produces tables where individual cells can be selected. Horizontally center tables on the page. Column headings must 'standalone' and not require searching the text to explain the terms. Do not embed the table's title as a header-row in the table.

**Photographs and Diagrams:** The use of color is encouraged. We recommend 300 DPI resolution at actual size. The legend should not be embedded in the photograph or diagram.

**Graphs:** Please make sure that bars, plot symbols, lines between plot symbols and indications of variability and statistical significance can be discriminated, even when viewed on a small screen or window. Include a key, axis labels and units that are easily readable. The legend should not be embedded in the graph.

**Equations:** These should be embedded in the text using the Microsoft Word equation editor.

## General Guidelines

Your entire manuscript should be Microsoft Word compatible and have one-inch margins. 8½ x 11 inch or A4 page size is acceptable. Please submit manuscripts via the web form. **Please keep back-up copies of all files you send us!**

There are certain things that you can do which will help enormously in the typesetting of your manuscript:

- Pages should be numbered consecutively throughout the manuscript.
- Please provide all measurements in SI units.
- Define all abbreviations the first time they occur – even well-known ones.
- Please use American English spelling and do not be offended if our editors make corrections. RDD is published in the United States, and this is our house style.
- If you use ®, <sup>TM</sup> or © symbols, please do this only once when the word is first mentioned.
- Please do not try to make the manuscript look as if it were the final published version. It should contain no layout formatting such as styles, borders or running headings. Please do not use any hyperlinks to footnotes, references or figure captions.
- Make sure that all abstracts have been carefully spell-checked. It is very helpful if authors (particularly those who do not speak English as their first language) solicit help from a colleague to proof their abstract before submission.
- Single quotation marks should surround 'concept' words, slang words or uncommon technical terms. Use double marks if quoting directly from a written or verbal source.
- Use only single spaces between words, and a single space at the end of each sentence.
- Do not indent new paragraphs but leave an extra line space between them.